Vivo Capital, LLC — 13F Holdings & Portfolio
CIK 1674712 · latest 13F-HR filed 2026-05-20
Vivo Capital, LLC manages $1.20B in 13F-reported U.S. long-equity assets across 46 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are ERAS (16.34%), PRAX (9.08%), TERN (5.85%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position, exited 0, added to 0, and trimmed 0.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$1.20B
Long-equity book
46
Distinct positions
2026-03-31
Filed 2026-05-20
+1 / −0 / ↑0 / ↓0
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Erasca Inc | ERAS | 29479A108 | $196.6M | 16.34% | 12,151,480 | SH |
| 2 | Praxis Precision Medicines | PRAX | 74006W207 | $109.2M | 9.08% | 338,895 | SH |
| 3 | Terns Pharmaceuticals Inc | TERN | 880881107 | $70.4M | 5.85% | 1,334,418 | SH |
| 4 | Trevi Therapeutics Inc | TRVI | 89532M101 | $60.8M | 5.05% | 5,094,668 | SH |
| 5 | DBV Technologies SA | DBVT | 23306J309 | $55.7M | 4.63% | 2,667,569 | SH |
| 6 | Compass Therapeutics Inc | CMPX | 20454B104 | $50.5M | 4.20% | 9,545,466 | SH |
| 7 | Tango Therapeutics Inc | TNGX | 87583X109 | $45.1M | 3.75% | 2,154,780 | SH |
| 8 | SAB Biotherapeutics Inc | SABS | 78397T202 | $43.7M | 3.64% | 11,420,000 | SH |
| 9 | Corvus Pharmaceuticals Holdings | CRVS | 221015100 | $41.0M | 3.41% | 2,805,816 | SH |
| 10 | Bright Minds Biosciences Inc | DRUG | 10919W405 | $40.7M | 3.38% | 557,172 | SH |
| 11 | Sinovac Biotech Ltd. | SVA | P8696W104 | $38.2M | 3.17% | 5,903,000 | SH |
| 12 | Dianthus Therapeutics Inc | DNTH | 252828108 | $29.7M | 2.47% | 353,998 | SH |
| 13 | Dyne Therapeutics Inc | DYN | 26818M108 | $28.2M | 2.35% | 1,557,466 | SH |
| 14 | Abivax SA - ADR | ABVX | 00370M103 | $26.7M | 2.22% | 239,539 | SH |
| 15 | Minerva Neurosciences Inc | NERV | 603380205 | $26.0M | 2.17% | 4,322,747 | SH |
| 16 | Aclaris Therapeutics, Inc. | ACRS | 00461U105 | $25.0M | 2.08% | 6,666,666 | SH |
| 17 | Oric Pharmaceuticals Inc | ORIC | 68622P109 | $23.4M | 1.95% | 1,848,786 | SH |
| 18 | Alto Neuroscience Inc | ANRO | 02157Q109 | $23.3M | 1.94% | 1,035,551 | SH |
| 19 | Sensei Biotherapeutics Inc | SNSE | 81728A207 | $22.8M | 1.89% | 722,020 | SH |
| 20 | Arrivent BioPharma Inc | AVBP | 04272N102 | $20.4M | 1.70% | 885,916 | SH |
| 21 | LB Pharmaceuticals Inc | LBRX | 50180M108 | $19.7M | 1.64% | 800,000 | SH |
| 22 | Veradermics Inc | MANE | 922967104 | $18.9M | 1.57% | 300,000 | SH |
| 23 | CAMP4 Therapeutics Inc | CAMP | 13463J101 | $18.7M | 1.56% | 4,246,568 | SH |
| 24 | Moonlake Immunotherapeutics | MLTX | 61559X104 | $18.6M | 1.55% | 1,000,000 | SH |
| 25 | Design Therapeutics Inc | DSGN | 25056L103 | $17.2M | 1.43% | 1,612,903 | SH |
| 26 | Cogent Biosciences Inc | COGT | 19240Q201 | $16.3M | 1.35% | 422,300 | SH |
| 27 | Geron Corp | GERN | 374163103 | $12.9M | 1.07% | 8,671,797 | SH |
| 28 | Unicycive Therapeutics | UNCY | 90466Y202 | $11.8M | 0.98% | 1,789,916 | SH |
| 29 | AN2 Therapeutics Inc | ANTX | 037326105 | $10.8M | 0.90% | 3,153,640 | SH |
| 30 | Olema Pharmaceuticals Inc | OLMA | 68062P106 | $10.0M | 0.83% | 671,843 | SH |
| 31 | Soleno Therapeutics Inc | SLNO | 834203309 | $9.9M | 0.82% | 294,909 | SH |
| 32 | Eupraxia Pharmaceuticals Inc | EPRX | 29842P105 | $9.8M | 0.81% | 1,350,000 | SH |
| 33 | Onkure Therapeutics Inc | OKUR | 68277Q105 | $8.0M | 0.66% | 1,927,710 | SH |
| 34 | Surrozen Inc | SRZN | 86889P208 | $7.6M | 0.63% | 260,000 | SH |
| 35 | ALX Oncology Holdings Inc | ALXO | 00166B105 | $6.4M | 0.53% | 3,184,713 | SH |
| 36 | Monopar Therapeutics Inc | MNPR | 61023L207 | $5.0M | 0.41% | 90,500 | SH |
| 37 | Satellos Bioscience Inc | MSLE | 80401L803 | $4.6M | 0.38% | 813,666 | SH |
| 38 | Pepgen Inc | PEPG | 713317105 | $4.1M | 0.34% | 2,325,000 | SH |
| 39 | Sera Prognostics Inc | SERA | 81749D107 | $3.4M | 0.28% | 1,650,440 | SH |
| 40 | Tenax Therapeutics Inc | TENX | 88032L605 | $3.3M | 0.28% | 208,333 | SH |
| 41 | Viridian Therapeutics Inc | VRDN | 92790C104 | $3.3M | 0.27% | 166,288 | SH |
| 42 | Instil Bio Inc | TIL | 45783C200 | $2.4M | 0.20% | 292,743 | SH |
| 43 | Pasithea Therapeutics Corp | KTTA | 70261F202 | $1.6M | 0.13% | 2,100,000 | SH |
| 44 | Compass Pathway PLC | CMPS | 20451W101 | $1.1M | 0.09% | 200,000 | SH |
| 45 | Bolt Therapeutics Inc | BOLT | 097702203 | $292.6K | 0.02% | 72,414 | SH |
| 46 | Precision Biosciences Inc | DTIL | 74019P207 | $25.7K | 0.00% | 4,675 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $1.20B | 45 | 0001213900-26-057929 |
| 2026-03-31 | 2026-05-20 | $1.20B | 46 | 0001213900-26-059247 |
| 2025-12-31 | 2026-02-13 | $1.55B | 47 | 0001213900-26-016236 |
| 2025-09-30 | 2025-11-14 | $1.24B | 47 | 0001213900-25-110767 |